Palvella Therapeutics has announced that clinical results from its Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN™ 3.9% rapamycin anhydrous gel will be presented at the upcoming International Society for the Study of Vascular Anomalies (ISSVA) World Congress on May 20, 2026. The presentation, led by Dr. James Treat from the Children’s Hospital of Philadelphia, will focus on the gel’s efficacy in treating microcystic lymphatic malformations and cutaneous venous malformations, highlighting statistically significant and clinically meaningful improvements observed in these patient populations.

The significance of these findings lies in the lack of FDA-approved therapies for serious and rare skin diseases and vascular malformations. The SELVA study demonstrated that QTORIN™ rapamycin effectively reduces the size and symptoms of microcystic lymphatic malformations, while the TOIVA study showcased similar benefits for cutaneous venous malformations. The results not only underscore the therapeutic potential of rapamycin in these conditions but also pave the way for possible regulatory advancements, as Palvella aims to pursue Breakthrough Therapy Designation based on this promising data.

The key takeaway from this development is the potential shift in treatment paradigms for patients with rare vascular anomalies. The successful outcomes from these trials could expedite the drug development timeline for QTORIN™ rapamycin and similar compounds, ultimately leading to faster access to effective therapies for patients suffering from these debilitating conditions. This research not only enhances our understanding of rapamycin’s applications but also reinforces the importance of targeted therapies in the landscape of rare disease management.

Source: globenewswire.com